0001104659-22-122476.txt : 20221128 0001104659-22-122476.hdr.sgml : 20221128 20221128170059 ACCESSION NUMBER: 0001104659-22-122476 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221125 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221128 DATE AS OF CHANGE: 20221128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: First Wave BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 221426337 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 8-K 1 tm2231455d2_8k.htm FORM 8-K
0001604191 false --12-31 0001604191 2022-11-25 2022-11-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): November 25, 2022

 

First Wave BioPharma, Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   001-37853   46-4993860
(State or other jurisdiction of
incorporation)		   (Commission File Number)   (IRS Employer Identification No.)

 

777 Yamato Road, Suite 502

Boca Raton, Florida

   33431
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (561) 589-7020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which

registered

Common Stock, par value $0.0001 per share   FWBI   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 3.03 Material Modification to Rights of Security Holders

 

The disclosure set forth in Item 5.03 below is hereby incorporated herein by reference.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

Series F Preferred Stock

 

On November 25, 2022, the Board of Directors (the “Board”) of First Wave BioPharma, Inc. (the “Company”) declared a dividend of 0.001 of a share of Series F Preferred Stock, par value $0.0001 per share (“Series F Preferred Stock”), for each outstanding share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) to stockholders of record at 5:00pm Eastern Time on December 5, 2022 (the “Record Date”).

 

General; Transferability. Shares of Series F Preferred Stock will be uncertificated and represented in book-entry form. No shares of Series F Preferred Stock may be transferred by the holder thereof except in connection with a transfer by such holder of any shares of Common Stock held by such holder, in which case a number of one one-thousandths (1/1,000ths) of a share of Series F Preferred Stock equal to the number of shares of Common Stock to be transferred by such holder will be automatically transferred to the transferee of such shares of Common Stock.

 

Voting Rights. Each share of Series F Preferred Stock will entitle the holder thereof to 1,000,000 votes per share (and, for the avoidance of doubt, each fraction of a share of Series F Preferred Stock will have a ratable number of votes). Thus, each 0.001 of a share of Series F Preferred Stock would entitle the holder thereof to 1,000 votes. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of Common Stock of the Company as a single class exclusively with respect to (1) any proposal (the “Reverse Stock Split Proposal”) to adopt an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to reclassify the outstanding shares of Common Stock into a smaller number of shares of Common Stock at a ratio specified in or determined in accordance with the terms of such amendment (the “Reverse Stock Split”) and (2) any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Reverse Stock Split (the “Adjournment Proposal”). The Series F Preferred Stock will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

 

Unless otherwise provided on any applicable proxy or ballot with respect to the voting on the Reverse Stock Split Proposal or the Adjournment Proposal, the vote of each share of Series F Preferred Stock (or fraction thereof) entitled to vote on the Reverse Stock Split Proposal, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split Proposal will be cast in the same manner as the vote, if any, of the share of Common Stock in respect of which such share of Series F Preferred Stock was issued as a dividend is cast on the Reverse Stock Split Proposal, the Adjournment Proposal or such other matter, as applicable, and the proxy or ballot with respect to shares of Common Stock held by any holder on whose behalf such proxy or ballot is submitted will be deemed to include all shares of Series F Preferred Stock (or fraction thereof) held by such holder. Holders of Series F Preferred Stock will not receive a separate ballot or proxy to cast votes with respect to the Series F Preferred Stock on the Reverse Stock Split Proposal, the Adjournment Proposal or any other matter brought before any meeting of stockholders held to vote on the Reverse Stock Split Proposal.

 

Dividend Rights. The holders of Series F Preferred Stock, as such, will not be entitled to receive dividends of any kind.

 

Liquidation Preference. The Series F Preferred Stock will rank senior to the Common Stock as to any distribution of assets upon a liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily (a “Dissolution”). Upon any Dissolution, each holder of outstanding shares of Series F Preferred Stock will be entitled to be paid out of the assets of the Company available for distribution to stockholders, prior and in preference to any distribution to the holders of Common Stock, an amount in cash equal to $0.0001 per outstanding share of Series F Preferred Stock.

 

 

 

 

Redemption. All shares of Series F Preferred Stock that are not present in person or by proxy at any meeting of stockholders held to vote on the Reverse Stock Split and the Adjournment Proposal as of immediately prior to the opening of the polls at such meeting (the “Initial Redemption Time”) will automatically be redeemed in whole, but not in part, by the Company at the Initial Redemption Time without further action on the part of the Company or the holder of shares of Series F Preferred Stock (the “Initial Redemption”). Any outstanding shares of Series F Preferred Stock that have not been redeemed pursuant to an Initial Redemption will be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board in its sole discretion, automatically and effective on such time and date specified by the Board in its sole discretion or (ii) automatically upon the effectiveness of the amendment to the Certificate of Incorporation implementing the Reverse Stock Split.

 

Each share of Series F Preferred Stock redeemed in any redemption described above will be redeemed in consideration for the right to receive an amount equal to $0.001 in cash for each ten whole shares of Series F Preferred Stock that are “beneficially owned” by the “beneficial owner” (as such terms are defined in the certificate of designation with respect to the Preferred Stock (the “Certificate of Designation”)) thereof as of immediately prior to the applicable redemption time and redeemed pursuant to such redemption. However, the redemption consideration in respect of the shares of Series F Preferred Stock (or fractions thereof) redeemed in any redemption described above: (i) will entitle the former beneficial owners of less than ten whole shares of Series F Preferred Stock redeemed in any redemption to no cash payment in respect thereof and (y) will, in the case of a former beneficial owner of a number of shares of Series F Preferred Stock (or fractions thereof) redeemed pursuant to any redemption that is not equal to a whole number that is a multiple of ten, entitle such beneficial owner to the same cash payment, if any, in respect of such redemption as would have been payable in such redemption to such beneficial owner if the number of shares (or fractions thereof) beneficially owned by such beneficial owner and redeemed pursuant to such redemption were rounded down to the nearest whole number that is a multiple of ten (such, that for example, the former beneficial owner of 25 shares of Series F Preferred Stock redeemed pursuant to any redemption will be entitled to receive the same cash payment in respect of such redemption as would have been payable to the former beneficial owner of 20 shares of Series F Preferred Stock redeemed pursuant to such redemption).

 

The Series F Preferred Stock is not be convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. The Series F Preferred Stock has no stated maturity and is not be subject to any sinking fund. The Series F Preferred Stock is not subject to any restriction on the redemption or repurchase of shares by the Company while there is any arrearage in the payment of dividends or sinking fund installments.

 

The Certificate of Designation was filed with the Delaware Secretary of State and became effective on November 28, 2022. The foregoing description of the Series F Preferred Stock does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, which is filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

On November 25, 2022, the Company issued a press release announcing the Series F Preferred Stock dividend. A copy of that press release is furnished as Exhibit 99.1 to this Current Report and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit No. Description
3.1 Certificate of Designation of the Series F Preferred Stock of the Company, dated November 28, 2022 (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on November 28, 2022, File No. 000-56497).
99.1 Press Release, dated November 25, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  First Wave BioPharma, Inc.
   
November 28, 2022 By: /s/ James Sapirstein
  Name: James Sapirstein
  Title: Chief Executive Officer

 

 

 EX-99.1 2 tm2231455d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

FIRST WAVE BIOPHARMA ANNOUNCES DISTRIBUTION OF

SERIES F PREFERRED STOCK

TO HOLDERS OF ITS COMMON STOCK

 

BOCA RATON, Fla., November 25, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-system therapies for gastrointestinal diseases, today announced that its Board of Directors declared a dividend of 0.001 of a share of newly-designated Series F Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on December 5, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of the Company’s common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series F Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per 0.001 of a share of Series F Preferred Stock).

 

All shares of Series F Preferred Stock that are not present in person or by proxy at the meeting of stockholders held to vote on the reverse stock split as of immediately prior to the opening of the polls at such meeting will automatically be redeemed by the Company. Any outstanding shares of Series F Preferred Stock that have not been so redeemed will be redeemed if such redemption is ordered by the Company’s Board of Directors or automatically upon the effectiveness of the amendment to the Company’s certificate of incorporation effecting the reverse stock split.

 

The Series F Preferred Stock will be uncertificated, and no shares of Series F Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Company’s common stock held by such holder. In that case, a number of one one-thousandths (1/1000ths) of a share of Series F Preferred Stock equal to the number of shares of the Company’s common stock to be transferred by such holder would be transferred to the transferee of such shares of common stock.

 

Further details regarding the Series F Preferred Stock will be contained in a Form 8-K to be filed by the Company with the Securities and Exchange Commission.

 

About First Wave BioPharma, Inc.

 

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple clinical stage programs built around its two proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-inflammatory properties. First Wave is advancing two Phase 2 clinical programs built around adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). In developing adrulipase, First Wave is seeking to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. The company is also advancing multiple programs involving niclosamide, including FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis, FW-UC for ulcerative colitis, and FW-CD for Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.

 

 

 

 

Forward-Looking Statements

 

This press release may contain certain statements relating to future results which are forward-looking statements. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including risks and uncertainties related to market conditions; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company will be able to regain and maintain compliance with Nasdaq’s continued listing criteria; the size of the potential markets for the Company’s drug candidates and its ability to service those markets; the effects of the First Wave Bio, Inc. acquisition, the related settlement and their effect on the Company’s business, operating results and financial prospects; and the Company’s current and future capital requirements and its ability to raise additional funds to satisfy its capital needs. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

 

For more information:
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
info@firstwavebio.com

 

Media contact:
Tiberend Strategic Advisors, Inc.
Bill Borden
(732) 910-1620
bborden@tiberend.com

 

Dave Schemelia
(609) 468-9325
dschemelia@tiberend.com

 

 

 EX-101.SCH 3 fwbi-20221125.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fwbi-20221125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fwbi-20221125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 25, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 25, 2022
Current Fiscal Year End Date --12-31
Entity File Number 001-37853
Entity Registrant Name First Wave BioPharma, Inc.
Entity Central Index Key 0001604191
Entity Tax Identification Number 46-4993860
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 777 Yamato Road
Entity Address, Address Line Two Suite 502
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code 561
Local Phone Number 589-7020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol FWBI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2231455d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001604191 2022-11-25 2022-11-25 iso4217:USD shares iso4217:USD shares 0001604191 false --12-31 8-K 2022-11-25 First Wave BioPharma, Inc. DE 001-37853 46-4993860 777 Yamato Road Suite 502 Boca Raton FL 33431 561 589-7020 false false false false Common Stock, par value $0.0001 per share FWBI NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://firstwavebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2231455d2_8k.htm fwbi-20221125.xsd fwbi-20221125_lab.xml fwbi-20221125_pre.xml tm2231455d2_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2231455d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2231455d2_8k.htm" ] }, "labelLink": { "local": [ "fwbi-20221125_lab.xml" ] }, "presentationLink": { "local": [ "fwbi-20221125_pre.xml" ] }, "schema": { "local": [ "fwbi-20221125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "FWBI", "nsuri": "http://firstwavebio.com/20221125", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231455d2_8k.htm", "contextRef": "From2022-11-25to2022-11-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://firstwavebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2231455d2_8k.htm", "contextRef": "From2022-11-25to2022-11-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://firstwavebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001104659-22-122476-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-122476-xbrl.zip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end